Health Care & Life Sciences » Biotechnology | Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc. | Mutual Funds

Mutual Funds that own Corbus Pharmaceuticals Holdings Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Fidelity Select Biotechnology Portfolio
3,366,167
5.88%
0
0.21%
07/31/2018
2,556,413
4.47%
63,036
3.27%
09/06/2018
Vanguard Total Stock Market Index Fund
1,312,967
2.29%
26,353
0%
07/31/2018
iShares Russell 2000 ETF
1,067,761
1.87%
-570
0.01%
09/06/2018
Vanguard Extended Market Index Fund
666,635
1.17%
0
0.01%
07/31/2018
iShares Nasdaq Biotechnology ETF
653,232
1.13%
-8,547
0.04%
09/06/2018
iShares Russell 2000 Growth ETF
474,673
0.83%
0
0.02%
09/06/2018
Fidelity Spartan Extended Market Index Fund
211,811
0.37%
0
0.01%
07/31/2018
Fidelity Advisor Biotechnology Fund
184,837
0.32%
-836,184
0.04%
07/31/2018
iShares Micro Cap ETF
133,248
0.23%
0
0.07%
09/06/2018

About Corbus Pharmaceuticals Holdings

View Profile
Address
500 River Ridge Drive
Norwood Massachusetts 02062
United States
Employees -
Website http://www.corbuspharma.com
Updated 07/08/2019
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.